Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey

Thumbnail Image

Files

Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients Experience from anEarly Access Program in Turkey.pdf (419.92 KB)

Date

2019-01-01

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

Abstract

Description

Keywords

Citation

URI

https://hdl.handle.net/11443/2813
 http://dx.doi.org/10.1016/j.jtho.2019.08.1166

Collections

WOS

Endorsement

Review

Supplemented By

Referenced By